South Korea
· Delayed Price · Currency is KRW BioInfra Life Science Statistics
Total Valuation
BioInfra Life Science has a market cap or net worth of KRW 2.92 billion.
| Market Cap | 2.92B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
BioInfra Life Science has 14.09 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 14.09M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 58.86% |
| Owned by Institutions (%) | 2.41% |
| Float | 8.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.57 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.67
| Current Ratio | 1.67 |
| Quick Ratio | 1.66 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.54 |
| Interest Coverage | -12.02 |
Financial Efficiency
Return on equity (ROE) is -746.61% and return on invested capital (ROIC) is -37.22%.
| Return on Equity (ROE) | -746.61% |
| Return on Assets (ROA) | -28.10% |
| Return on Capital (ROIC) | -37.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.41% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -41.41% |
| 50-Day Moving Average | 272.32 |
| 200-Day Moving Average | 304.42 |
| Relative Strength Index (RSI) | 37.77 |
| Average Volume (20 Days) | 8,166 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioInfra Life Science had revenue of KRW 1.78 billion and -3.59 billion in losses. Loss per share was -266.28.
| Revenue | 1.78B |
| Gross Profit | 825.48M |
| Operating Income | -3.55B |
| Pretax Income | -3.59B |
| Net Income | -3.59B |
| EBITDA | -3.18B |
| EBIT | -3.55B |
| Loss Per Share | -266.28 |
Balance Sheet
The company has 7.49 billion in cash and 10.46 billion in debt, giving a net cash position of -2.97 billion or -210.80 per share.
| Cash & Cash Equivalents | 7.49B |
| Total Debt | 10.46B |
| Net Cash | -2.97B |
| Net Cash Per Share | -210.80 |
| Equity (Book Value) | -1.21B |
| Book Value Per Share | -102.70 |
| Working Capital | 3.58B |
Cash Flow
In the last 12 months, operating cash flow was -2.87 billion and capital expenditures -81.61 million, giving a free cash flow of -2.95 billion.
| Operating Cash Flow | -2.87B |
| Capital Expenditures | -81.61M |
| Free Cash Flow | -2.95B |
| FCF Per Share | -209.72 |
Margins
Gross margin is 46.40%, with operating and profit margins of -199.78% and -202.04%.
| Gross Margin | 46.40% |
| Operating Margin | -199.78% |
| Pretax Margin | -202.04% |
| Profit Margin | -202.04% |
| EBITDA Margin | -178.62% |
| EBIT Margin | -199.78% |
| FCF Margin | -166.11% |
Dividends & Yields
BioInfra Life Science does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.59% |
| Shareholder Yield | 2.59% |
| Earnings Yield | -128.64% |
| FCF Yield | -101.31% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioInfra Life Science has an Altman Z-Score of -4.65. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.65 |
| Piotroski F-Score | n/a |